This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Jubilant Episcribe LLC. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Shivani Garapaty: Innovator in Therapeutic Compounds
Introduction
Shivani Garapaty is a prominent inventor based in Bengaluru, India. She has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target critical cellular processes. Her work focuses on creating innovative solutions for various diseases, showcasing her dedication to improving healthcare outcomes.
Latest Patents
Shivani holds a patent for "Heterocyclic compounds as PRMT5 inhibitors." This patent describes compounds of Formula I, Formula Ia, and Formula Ib, along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs. These compounds are designed to inhibit PRMT5 and are useful as therapeutic agents for diseases related to cellular growth, including malignant tumors, schizophrenia, Alzheimer's disease, and Parkinson's disease. She has 1 patent to her name.
Career Highlights
Shivani is currently employed at Jubilant Episcribe LLC, where she continues to advance her research and development efforts. Her work at the company emphasizes the importance of innovation in the pharmaceutical industry, particularly in the creation of new therapeutic agents.
Collaborations
Shivani collaborates with talented professionals in her field, including Tamizharasan Natarajan and Sridharan Rajagopal. These collaborations enhance her research capabilities and contribute to the success of her projects.
Conclusion
Shivani Garapaty is a dedicated inventor whose work in developing PRMT5 inhibitors demonstrates her commitment to addressing significant health challenges. Her contributions to medicinal chemistry are paving the way for new therapeutic options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile